Other languages Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
7.39 ^USD	+3.21%		+2.07%	+3.65%

May. 14	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant Acute Myeloid Leukemia Patients At the European Hematology Association 2024 Congress	CI
May. 02	Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant Acute Myeloid Leukemia Patients At the European Hematology Association 2024 Congress	May. 14
Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Shattuck Labs, Inc. Announces Board Appointments	Mar. 04
Sector Update: Health Care Stocks Rising Late Afternoon	Mar. 01
Sector Update: Health Care Stocks Advance Friday Afternoon	Mar. 01
Shattuck Labs Shares Rise as Q4 Net Loss Narrows	Mar. 01
Shattuck Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Shattuck Labs, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
Shattuck Labs Collaborates With Ono Pharmaceutical to Develop Fusion Proteins	Feb. 14
Shattuck Labs, Inc. Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	Feb. 13
Shattuck Labs Insider Sold Shares Worth $250,000, According to a Recent SEC Filing	Jan. 16
Shattuck Labs, Inc. Files Initial Topline Dose-Exp Expansion Data from Its Ongoing Phase 1A/B Clinical Trial of Sl-172154 in Frontline Tp53m Aml and Tp53m Aml Patients	Dec. 21
Shattuck Labs Shares Soar as Blood Cancer Therapy Trial Yields 79% Objective Response Rate	Dec. 13
Top Midday Gainers	Dec. 13
Fed Meeting Awaited as Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Wednesday	Dec. 13
Top Premarket Gainers	Dec. 13
Shattuck Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia and Higher-Mds) Patients At the American Society of Hematology 2023 Annual Meeting	Nov. 02
Shattuck Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Other languages

Filters